Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

Quoin Pharmaceuticals  / Equity Bottom-Up

<ul><li>With a strategy to design products to treat multiple indications, QNRX intends to study QRX003 for several conditions & build a database supporting its efficacy and safety as a treatment for a range of dermatological conditions.</li><li>The company plans to begin a clinical study of QRX003 in Peeling Skin Syndrome (PSS), a rare autosomal disease that has no approved treatment.</li><li>By developing its assets for multiple indications, QNRX aims to increase the potential for an expedited regulatory pathway, attain economies of scale on R&D, sales & marketing and other costs and potentially broaden the target market if/when commercial sales launch.</li></ul>

With a strategy to design products to treat multiple indications, QNRX intends to study QRX003 for several conditions & build a database supporting its efficacy and safety as a treatment for a range of dermatological conditions.The company plans to begin a clinical study of QRX003 in Peeling Skin Syndrome (PSS), a rare autosomal disease that has no approved treatment.By developing its assets for multiple indications, QNRX aims to increase the potential for an expedited regulatory pathway, attain economies of scale on R&D, sales & marketing and other costs and potentially broaden the target market if/when commercial sales launch.

QNRX: Assessing QRX003 For Multiple Conditions  Opening International Netherton Syndrome Clinical Sites

<ul><li>Between cash on hand and a recent arrangement for an equity line of credit for up to $8M, management believes that through its measures, it has extended its cash to maintain activities into late 2025.</li><li>This is expected to enable Quoin to continue moving QRX003 ahead through NS clinical trials and recent FDA clearance to recruit subjects 14 and older also allows Quoin to broaden the pool of people eligible to participate in the studies and thereby facilitate recruitment efforts.</li><li>Expanding the number of participants to an aggregate of 50 NS subjects also is expected to contribute to a more robust database to present for potential regulatory approval.</li></ul>

Between cash on hand and a recent arrangement for an equity line of credit for up to $8M, management believes that through its measures, it has extended its cash to maintain activities into late 2025.This is expected to enable Quoin to continue moving QRX003 ahead through NS clinical trials and recent FDA clearance to recruit subjects 14 and older also allows Quoin to broaden the pool of people eligible to participate in the studies and thereby facilitate recruitment efforts.Expanding the number of participants to an aggregate of 50 NS subjects also is expected to contribute to a more robust database to present for potential regulatory approval.

QNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 Approvals

Israel

Quoin Pharmaceuticals Ltd. operates as a specialty pharmaceutical company. The Company focuses on developing and commercializing therapeutic products that treat rare and orphan diseases. Quoin Pharmaceuticals serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Quoin Pharmaceuticals (QNRX US)

QNRX: Assessing QRX003 For Multiple Conditions Opening International Netherton Syndrome Clinical Sites

With a strategy to design products to treat multiple indications, QNRX intends to study QRX003 for several conditions & build a database...

Zacks Small Cap Research

QNRX: Protocol Modifications Potentially Accelerate, Expand QRX003 Approvals

Between cash on hand and a recent arrangement for an equity line of credit for up to $8M, management believes that through its measures, it has...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)